Cargando…
Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291174/ https://www.ncbi.nlm.nih.gov/pubmed/30613355 http://dx.doi.org/10.18632/oncotarget.26431 |
| _version_ | 1783380220019998720 |
|---|---|
| author | Cazzaniga, Marina Verusio, Claudio Ciccarese, Mariangela Fumagalli, Alberto Sartori, Donata Valerio, Maria Rosaria Airoldi, Mario Moretti, Gabriella Ficorella, Corrado Arcangeli, Valentina Diodati, Lucrezia Zambelli, Alberto Febbraro, Antonio Generali, Daniele Pistelli, Mirco Garrone, Ornella Musolino, Antonino Vici, Patrizia Maur, Michela Mentuccia, Lucia La Verde, Nicla Bianchi, Giulia Artale, Salvatore Blasi, Livio Piezzo, Michela Atzori, Francesco Turletti, Anna Benedetto, Chiara Cursano, Maria Concetta Fabi, Alessandra Gebbia, Vittorio Schirone, Alessio Palumbo, Raffaella Ferzi, Antonella Frassoldati, Antonio Scavelli, Claudio Clivio, Luca Torri, Valter |
| author_facet | Cazzaniga, Marina Verusio, Claudio Ciccarese, Mariangela Fumagalli, Alberto Sartori, Donata Valerio, Maria Rosaria Airoldi, Mario Moretti, Gabriella Ficorella, Corrado Arcangeli, Valentina Diodati, Lucrezia Zambelli, Alberto Febbraro, Antonio Generali, Daniele Pistelli, Mirco Garrone, Ornella Musolino, Antonino Vici, Patrizia Maur, Michela Mentuccia, Lucia La Verde, Nicla Bianchi, Giulia Artale, Salvatore Blasi, Livio Piezzo, Michela Atzori, Francesco Turletti, Anna Benedetto, Chiara Cursano, Maria Concetta Fabi, Alessandra Gebbia, Vittorio Schirone, Alessio Palumbo, Raffaella Ferzi, Antonella Frassoldati, Antonio Scavelli, Claudio Clivio, Luca Torri, Valter |
| author_sort | Cazzaniga, Marina |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6291174 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | Impact Journals LLC |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-62911742019-01-04 Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study Cazzaniga, Marina Verusio, Claudio Ciccarese, Mariangela Fumagalli, Alberto Sartori, Donata Valerio, Maria Rosaria Airoldi, Mario Moretti, Gabriella Ficorella, Corrado Arcangeli, Valentina Diodati, Lucrezia Zambelli, Alberto Febbraro, Antonio Generali, Daniele Pistelli, Mirco Garrone, Ornella Musolino, Antonino Vici, Patrizia Maur, Michela Mentuccia, Lucia La Verde, Nicla Bianchi, Giulia Artale, Salvatore Blasi, Livio Piezzo, Michela Atzori, Francesco Turletti, Anna Benedetto, Chiara Cursano, Maria Concetta Fabi, Alessandra Gebbia, Vittorio Schirone, Alessio Palumbo, Raffaella Ferzi, Antonella Frassoldati, Antonio Scavelli, Claudio Clivio, Luca Torri, Valter Oncotarget Correction Impact Journals LLC 2018-11-30 /pmc/articles/PMC6291174/ /pubmed/30613355 http://dx.doi.org/10.18632/oncotarget.26431 Text en Copyright: © 2018 Cazzaniga et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
| spellingShingle | Correction Cazzaniga, Marina Verusio, Claudio Ciccarese, Mariangela Fumagalli, Alberto Sartori, Donata Valerio, Maria Rosaria Airoldi, Mario Moretti, Gabriella Ficorella, Corrado Arcangeli, Valentina Diodati, Lucrezia Zambelli, Alberto Febbraro, Antonio Generali, Daniele Pistelli, Mirco Garrone, Ornella Musolino, Antonino Vici, Patrizia Maur, Michela Mentuccia, Lucia La Verde, Nicla Bianchi, Giulia Artale, Salvatore Blasi, Livio Piezzo, Michela Atzori, Francesco Turletti, Anna Benedetto, Chiara Cursano, Maria Concetta Fabi, Alessandra Gebbia, Vittorio Schirone, Alessio Palumbo, Raffaella Ferzi, Antonella Frassoldati, Antonio Scavelli, Claudio Clivio, Luca Torri, Valter Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study |
| title | Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study |
| title_full | Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study |
| title_fullStr | Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study |
| title_full_unstemmed | Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study |
| title_short | Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study |
| title_sort | correction 2: everolimus (eve) and exemestane (exe) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the eva study |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291174/ https://www.ncbi.nlm.nih.gov/pubmed/30613355 http://dx.doi.org/10.18632/oncotarget.26431 |
| work_keys_str_mv | AT cazzanigamarina correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT verusioclaudio correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT ciccaresemariangela correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT fumagallialberto correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT sartoridonata correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT valeriomariarosaria correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT airoldimario correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT morettigabriella correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT ficorellacorrado correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT arcangelivalentina correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT diodatilucrezia correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT zambellialberto correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT febbraroantonio correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT generalidaniele correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT pistellimirco correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT garroneornella correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT musolinoantonino correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT vicipatrizia correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT maurmichela correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT mentuccialucia correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT laverdenicla correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT bianchigiulia correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT artalesalvatore correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT blasilivio correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT piezzomichela correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT atzorifrancesco correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT turlettianna correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT benedettochiara correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT cursanomariaconcetta correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT fabialessandra correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT gebbiavittorio correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT schironealessio correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT palumboraffaella correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT ferziantonella correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT frassoldatiantonio correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT scavelliclaudio correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT clivioluca correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy AT torrivalter correction2everolimuseveandexemestaneexeinpatientswithadvancedbreastcanceraged65yearsnewlessonsforclinicalpracticefromtheevastudy |